Eli Lilly and Company (NYSE:LLY) Shares Bought by Linden Thomas Advisory Services LLC

Linden Thomas Advisory Services LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 6.4% in the fourth quarter, HoldingsChannel reports. The fund owned 8,633 shares of the company’s stock after buying an additional 518 shares during the period. Eli Lilly and Company makes up about 0.9% of Linden Thomas Advisory Services LLC’s portfolio, making the stock its 5th largest holding. Linden Thomas Advisory Services LLC’s holdings in Eli Lilly and Company were worth $5,032,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Lipe & Dalton acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $26,000. Thompson Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company in the third quarter valued at $27,000. Legacy Financial Group LLC purchased a new stake in shares of Eli Lilly and Company during the third quarter valued at $35,000. Optiver Holding B.V. purchased a new stake in shares of Eli Lilly and Company during the third quarter valued at $36,000. Finally, Family CFO Inc purchased a new stake in shares of Eli Lilly and Company during the third quarter valued at $40,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Buying and Selling

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Stock Up 1.8 %

Shares of LLY stock traded up $13.06 on Tuesday, reaching $744.39. 1,120,795 shares of the company were exchanged, compared to its average volume of 3,039,026. Eli Lilly and Company has a one year low of $370.68 and a one year high of $800.78. The company has a market cap of $707.29 billion, a price-to-earnings ratio of 127.57, a PEG ratio of 1.58 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The company has a 50-day moving average of $763.83 and a 200-day moving average of $662.78.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. During the same period in the previous year, the business earned $2.09 EPS. Eli Lilly and Company’s revenue was up 28.1% compared to the same quarter last year. Analysts anticipate that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on LLY shares. DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a report on Wednesday, February 21st. Bank of America upped their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Barclays upped their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. JPMorgan Chase & Co. upped their price target on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research note on Friday, March 15th. Finally, Citigroup upped their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.